Completed OBSERVATIONAL NCT01227213

The Vascular and Metabolic Effects of Sunitinib in Patients With Metastatic Renal Cell Carcinoma

Sponsor: Dutch Cancer Society

Conditions Hypertension Insulin Sensitivity Renal Cell Carcinoma Renal Function

Updated 11 times since 2017 Last updated: Oct 29, 2015 Started: Nov 30, 2010 Primary completion: Nov 30, 2013 Completion: Nov 30, 2013

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This observational or N/A phase trial investigates Hypertension and Insulin Sensitivity and is currently completed. Dutch Cancer Society leads this study, which shows 11 recorded versions since 2010 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

11 versions recorded

Sep 2024 — Present [monthly]

Completed
Jul 2024 — Sep 2024 [monthly]

Completed
Mar 2022 — Jul 2024 [monthly]

Completed
Dec 2021 — Mar 2022 [monthly]

Completed
Jan 2021 — Dec 2021 [monthly]

Completed

▶ Show 6 earlier versions

Nov 2020 — Jan 2021 [monthly]

Completed
Jun 2018 — Nov 2020 [monthly]

Completed
May 2018 — Jun 2018 [monthly]

Completed
Apr 2018 — May 2018 [monthly]

Completed

Phase: NA → None
Aug 2017 — Apr 2018 [monthly]

Completed NA
Jan 2017 — Aug 2017 [monthly]

Completed NA

First recorded

Nov 2010

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Dutch Cancer Society
Radboud University Medical Center

Data source: Radboud University Medical Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Nijmegen, Netherlands